Gaston Soria

Diving into the critical bridge between chemical innovation and clinical success, this workshop addresses the identified gap in biological validation. Moving from in vitro chemistry too predictable in vivo performance requires chemists and biologists to collaboratively design ADCs with an optimized therapeutic index from the outset.

This is a must-attend for chemistry and protein engineering teams looking to ground their technical strategies in biological reality and improve translatability by:

• Correlating specific linker chemistries and conjugation sites with tumor microenvironment biology and patient-specific PK/PD data to build predictive models for how chemical modifications influence clearance rates, tumor exposure, and ultimately efficacy and safety margins
• Designing and interpreting relevant in vivo and ex vivo studies to validate novel linker or conjugation technologies, moving beyond simple stability assays to demonstrate a direct impact on widening the therapeutic window in resistant or sensitive tumor model
• Establishing a framework for early-stage decision-making that integrates analytical chemistry data, in vitro potency, and preliminary PK insights to select the most promising ADC candidate for further development, de-risking the path to the clinic